NEW ORLEANS — Patients recently treated with bendamustine had significantly lower response rates to subsequent chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma, data presented at ASH Annual Meeting and Exposition showed.
Results from the retrospective analysis revealed surprisingly shorter survival among patients who received bendamustine in the 9 months prior to cellular therapy apheresis, indicating a possible lymphotoxic effect on CAR T-cell production.
However, researchers did not observe significant differences in safety or durability when comparing those with